TICKERNERD
Menu
PMIHealthcare · Medical Devices

PMI Stock Forecast: Picard Medical, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$3.21
+5.94% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 33 of 100 as at 22 Aug 2026 — in the lower half.

Market cap
$6.6M
Ticker Nerd rank
33 / 100
Median analyst target
—
Analysts covering
1
Total return, dividends reinvested
1W
−9.1%
1M
−46.9%
YTD
−96.3%
From high
−99.5%
From low
+5.9%
$3
$660
Range since 29 Aug 2025, adjusted closes · the dot is the last close
Ticker Nerd rank

PMI stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Picard Medical, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
33 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
94
Accruals
82
Issuance
73
Revisions
59
Growth
45
Value
10
Momentum
9
Quality
6
Volatility
1

Size (94): Smaller than most of the companies we track.

Volatility (1): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

PMI stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on PMI, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, since 29 Aug 2025Adjusted close, US dollars
$0$100$200$300$400$500$600Oct 25Jan 26Apr 26Jul 26PMI

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says1 analysts
0 Buy1 Hold0 Sell
Recent analyst actionsNewest first
DateFirmActionRatingTarget
3 June 2026HC Wainwright & Co.ReiteratesNeutral—
18 May 2026HC Wainwright & Co.InitiatesNeutral—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. PMI appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

PMI analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

Picard Medical, Inc. (PMI) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.1×

Cheaper than 77% of US stocks

Price / sales
1.0×

Cheaper than 69% of US stocks

Price / book
3.8×

Cheaper than 28% of US stocks

EV / EBITDA
−0.6×

Cheaper than 64% of US stocks

Growth & margins
Revenue growth (YoY)
39.1%

Higher than 83% of US stocks

Earnings growth (YoY)
—
Gross margin
23.9%

Higher than 27% of US stocks

Operating margin
−156.7%

Higher than 12% of US stocks

Net margin
−4.1%

Higher than 25% of US stocks

Returns & dividend
Return on equity
−712.6%

Higher than 2% of US stocks

Return on assets
−93.6%

Higher than 3% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

PMI vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
PMIPicard Medical, Inc.$6.6M
33
CODXCo-Diagnostics, Inc.$7.6M
37
INBSIntelligent Bio Solutions, Inc.$7.6M
9
NXLNexalin Technology, Inc.$7.3M
38
ICCMIceCure Medical Ltd.$6.8M
38
AIDX20/20 Biolabs, Inc.$6.8M
5
NVNOenVVeno Medical Corp.$6.7M
33

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Picard Medical, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest PMI news & analysis

Picard Medical Reports Second Quarter 2026 Financial Results

GlobeNewsWire · 19 Aug 2026positive

Picard Medical, Inc. reported its financial results for the second quarter ended June 30, 2026, showing a 39% increase in revenue and a 16% decrease in net loss. Year-to-date revenue rose 50%, with approximately $0.9 million in gross profit.

Why it matters — PMI watchers would care because the company reported higher revenue and a reduced net loss, indicating improving financial performance for the maker of the total artificial heart.

Picard Medical / SynCardia Presents Emperor Total Artificial Heart Architecture for the First Time at IEEE EMBC 2026

GlobeNewsWire · 31 July 2026positive

Picard Medical/SynCardia presented the architecture of its Emperor Total Artificial Heart for the first time at the IEEE EMBC 2026 conference, marking the initial public scientific disclosure of its next-generation total artificial heart platform.

Why it matters — This first detailed public presentation signals a significant research and development milestone for PMI's total artificial heart program, offering the biomedical community an early look at the platform.

Picard Medical / SynCardia to Present Next-Generation Emperor Total Artificial Heart Technology at IEEE EMBC 2026

GlobeNewsWire · 27 July 2026positive

Picard Medical and its subsidiary SynCardia announced that the next-generation Emperor Total Artificial Heart technology will be presented at the IEEE EMBC 2026 conference in Toronto, marking the first scientific presentation of the Emperor Drive System architecture to the biomedical engineering community.

Why it matters — This presentation signals progress in the development of Picard's next-generation artificial heart technology, which could expand the company's product pipeline beyond its currently approved total artificial heart.

Picard Medical Receives NYSE American Acceptance of Compliance Plan

GlobeNewsWire · 27 July 2026positive

Picard Medical announced that the NYSE American has accepted the company's compliance plan. The company said it continues advancing its long-term growth strategy under the accepted plan.

Why it matters — Acceptance of the compliance plan by NYSE American removes a potential delisting risk and allows Picard Medical to focus on its long-term growth strategy without exchange-listing uncertainty.

FAQ

Frequently asked questions about PMI stock

Is PMI stock a buy right now?

Of the 1 analysts covering Picard Medical, Inc., 0 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Picard Medical, Inc. 33 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank PMI?

As at 22 Aug 2026, Picard Medical, Inc. ranks 33 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (94 of 100).

What is the PMI stock forecast for 2030?

No analyst covering Picard Medical, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PMI are extrapolating price history, which says nothing about the business.

What does Picard Medical, Inc. do?

Picard Medical, Inc. is a healthcare equipment company specializing in the development, manufacturing, and commercialization of advanced medical device solutions, with a primary focus on cardiac care.

What is the latest news on PMI?

The most recent item we track (GlobeNewsWire, 19 Aug 2026): "Picard Medical Reports Second Quarter 2026 Financial Results". Picard Medical, Inc. reported its financial results for the second quarter ended June 30, 2026, showing a 39% increase in revenue and a 16% decrease in net loss. Year-to-date revenue rose 50%, with approximately $0.9 million in gross profit.

Company

About Picard Medical, Inc.

Picard Medical, Inc. is a healthcare equipment company specializing in the development, manufacturing, and commercialization of advanced medical device solutions, with a primary focus on cardiac care. Its core product is the implantable SynCardia Total Artificial Heart, which is designed to temporarily replace the full function of a human heart in patients suffering from end-stage heart failure. This total artificial heart is the only system of its kind approved by both the U.S. Food and Drug Administration and Health Canada, and it is recognized globally as the most widely used and clinically studied artificial heart technology. Over 2,100 SynCardia systems have been implanted across 27 countries, serving as a critical bridge to heart transplantation for those with severe biventricular failure. As the parent company of SynCardia Systems, LLC, Picard Medical, Inc. plays a vital role in advancing life-saving cardiac technologies and addressing the needs of patients with advanced heart disease. Its innovative products underpin its significance within the medical devices sector, contributing to major advancements in artificial organ technology and modern cardiovascular treatment.

CEO Dr. Yuncai Fang Ph.D. · 75 employees · United States · https://www.picardmedical.com